Compare TRDA & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | BYND |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.4M | 446.9M |
| IPO Year | 2021 | 2019 |
| Metric | TRDA | BYND |
|---|---|---|
| Price | $11.67 | $0.94 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 7 |
| Target Price | ★ $20.00 | $1.70 |
| AVG Volume (30 Days) | 200.0K | ★ 54.8M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,520,000.00 | ★ $290,565,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $0.50 |
| 52 Week High | $14.27 | $7.69 |
| Indicator | TRDA | BYND |
|---|---|---|
| Relative Strength Index (RSI) | 64.79 | 44.53 |
| Support Level | $10.34 | $0.90 |
| Resistance Level | $11.49 | $1.11 |
| Average True Range (ATR) | 0.72 | 0.09 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 83.51 | 35.41 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.